Cardiovascular White Papers & Case Studies

  1. Optimizing Cardiovascular Clinical Trials With Technology
    9/16/2015

    The extraordinary advances in cardiovascular medicine over the past decades have extended and improved countless lives. Drugs for heart-related disease make up one of the biggest selling areas, with hypertension medications alone expected to reach over $24 billion in global sales in 2015. Real successes in reducing the death rate from myocardial infarction and controlling blood pressure and cholesterol are some of the true successes of modern medicine.

  2. Cardio-Metabolic: Clinical Development and Consultative Services
    6/5/2015

    PRA Health Sciences (PRA) provides comprehensive clinical development and consultative services to support our clients’ cardio-metabolic studies.

  3. Cutting-Edge Analytics Transform Global Cardiovascular Post-Marketing Commitment
    5/8/2015

    A global real world safety study program, mandated by various regulatory bodies, to confirm risk/benefit profile for a novel oral anticoagulant.

  4. Rare Diseases Clinical Trial Services
    12/17/2014

    Clinical development involving rare diseases poses a unique set of medical, scientific, and operational challenges. 

  5. The Environmental Impact of Clinical Trials
    8/8/2013

    For many years it has been almost universally accepted that there are various sources that may impact or cause disease among which biological, social, and environmental differences have all been investigated. Many clinical trials have been conducted to assess the impact of the environment on outcomes e.g., the effect of the environment on the outcome of studies assessing the efficacy of drugs for patients with dry-eye syndrome, the impact of diet on obesity and cardiovascular disease, and the impact of the environment on autoimmune diseases have all been studied, as have many other interactions.

  6. Healthcare Company Expects Online Collaboration To Save Millions Of Euros
    7/2/2013

    Sanofi is a multinational pharmaceutical company engaged in the research and development, manufacturing, and marketing of prescription drugs, vaccines, and over-the-counter healthcare products.

  7. Overcoming Clinical Challenges In Metabolic And Cardiovascular Disease With Metabolomics
    4/10/2013

    Metabolic diseases (e.g. obesity, type 2 diabetes, and hypertension) are a rapidly expanding health care concern. Although there is a high demand for novel therapies, the challenges are substantial as existing drugs typically fail due to lack of efficacy or safety, and clinical studies often extremely large and protracted. 

  8. Streamline And Accelerate A Drug Development Plan Using The 505(b)(2) Pathway
    2/19/2013

    An international pharmaceutical company approached Camargo Pharmaceutical Services to help navigate the Food and Drug Administration (FDA) 505(b)(2) approval pathway for a promising drug under development designated for patients with cardiovascular disease. Product X is a prodrug that is converted in one metabolism-dependent step to produce the active metabolite of an approved drug.

  9. Imaging For Cadiovascular Trials
    8/9/2012

    ICON Medical Imaging’s role as a medical imaging and endpoint core laboratory is to help sponsors assess the effect of therapies by independent and rigorous assessment of clinical and imaging endpoints.

  10. Precise Cold-Chain Logistics Supports Global Study Of Heart Disease
    5/22/2012

    The challenge involved the precise cold storage temperatures (between 2-8°C) required to assure the integrity of the strips during the transfer and storage of the product to various sites around the globe.